FindTrial
Sign In

Short-term MRI for Treatment Response Evaluation/Prediction of HCC Treated With TARE

Short Term Magnetic Resonance Imaging (MRI) for Treatment Response Evaluation and Prognosis Prediction in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Radioembolization (TARE)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03731910
Enrollment
35
Registered
2018-11-06
Start date
2018-12-11
Completion date
2023-06-30
Last updated
2021-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Keywords

MRI

Brief summary

This study aims to investigate the value of early change at MRI in HCC treated with TARE, for evaluation/prediction of treatment response and prognosis.

Interventions

DIAGNOSTIC_TESTMRI

liver MRI using standard dose of extracellular agent. It includes dynamic contrast-enhanced MRI and diffusion weighted image.

Sponsors

Dongkook Lifesicence
CollaboratorUNKNOWN
Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Intermediate or locally advanced HCC according to Hong Kong Liver Cancer guideline * Scheduled for transarterial radioembolization (TARE) * sign informed consent

Exclusion criteria

* Any absolute or relative contra-indication of contrast-enhanced MRI * History of other local treatment before TARE in 3 weeks

Design outcomes

Primary

MeasureTime frameDescription
Treatment response mRECIST1 month after last MRItreatment response using mRECIST

Secondary

MeasureTime frameDescription
Tumor diffusion1 months after last MRImeasured with diffusion-weighted image sequence
Tumor perfusion1 months after last MRImeasured with dynamic contrast-enhanced imaging
Treatment response LI-RADS1 months after last MRItreatment response using LI-RADSv 2018 treatment response category
Treatment response volumetric1 months after last MRItreatment response using volumetric response criteria
Time to Progression24 months after TARETime until to definite progression on follow-up images

Countries

South Korea

Contacts

Primary ContactHyun Hee Lee, RN
redlion55@naver.com82-2-2072-4177
Backup ContactJeong Hee Yoon, MD
cinamon1@snu.ac.kr82-2-2072-2584

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026